FDA scraps biosimilar guidance, saving hospitals EHR headaches

The FDA no longer plans to implement a guidance outlining a new naming protocol for biologics and biosimilars. The guidance would have required hospitals to spend hundreds of millions to overhaul their EHR systems.

Read the full post on Modern Healthcare Breaking News